{ "symbol": "TWST", "company": "Twist Bioscience Corporation", "generated_at": "2026-06-24T07:36:53.661Z", "event_count": 8, "events": [ { "type": "pipeline_event", "ts": "2026-06-20T12:08:02.545Z", "stage": "scout", "outcome": "unparseable", "reason": null, "trigger": "[form4_cluster] 5 Form 4 filings in last 14 days · 5 real trades", "source": "hunter" }, { "type": "scout_dossier", "ts": "2026-06-20T12:08:02.517Z", "summary": "{\"symbol\":\"TWST\",\"company\":\"Twist Bioscience Corporation\",\"investigation_summary\":\"The investigation triggered by 30 Form 4 filings in 14 days is almost entirely routine tax-withholding sales (RSU vesting 'sell to cover') and pre-scheduled 10b5-1 option exercises — not open-market discretionary buying. The CEO's May 28, 2026 filing explicitly shows a Rule 10b5-1 plan adopted in May 2025 with exerc", "verdict": "unparseable", "tool_calls": 23, "walltime_min": 11, "debug_path": "dossiers/2026-06-20-TWST.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-06-13T16:40:05.931Z", "summary": "The Form 4 cluster trigger (8 filings / 5 trades in 14 days) proved to be entirely RSU vesting sell-to-cover transactions — not discretionary open-market buys. CEO Leproust's sole activity was exercising pre-existing options under a May 2025 Rule 10b5-1 plan and selling at $65–69. No insider has made an open-market PURCHASE in the trailing period. Simultaneously, Cathie Wood / ARK Invest has been systematically trimming TWST across multiple weeks in June (reported $279M in weekly liquidations). The stock is up ~139% YTD from $32 to $76, near its 52-week high of $80.50 set June 4. With negative FCF (-$58M TTM), no path to profitability visible in the forward model, and elevated IV (62–81%), there is no mispricing edge, no real insider signal, and no income thesis at this level.", "verdict": "no_anomaly", "confidence": 5, "tool_calls": 22, "walltime_min": 22, "debug_path": "dossiers/2026-06-13-TWST.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-29T09:07:13.291Z", "summary": "Twist Bioscience is a silicon-chip-based synthetic DNA manufacturer with $376M FY2025 revenue (19% growth), 52%+ gross margins, and consistent quarterly sequential growth. The Form 4 cluster of 9 filings in 14 days resolves almost entirely to sell-to-cover tax withholding on RSU vesting events (S codes, not P purchases) plus pre-established 10b5-1 plans — there are zero open-market discretionary insider buy transactions during this period. CEO Leproust exercised deep ITM options ($8.82 strike) and sold ~$3.2M of shares, all under a prior 10b5-1 plan adopted May 2025. The stock is at an all-time high (+147% YTD), deeply unprofitable (forward P/E N/A, EV/EBITDA -38x), yet commands 35-40x forward revenue — leaving virtually no margin of safety for the long thesis. A path to adjusted EBITDA breakeven in Q4 FY2026 is a real catalyst if achieved but is ~5 months away and uncertain given recent EPS miss (-12.58% surprise last quarter). The DNA synthesis market TAM ($30B by 2035) and new product launches (Complex Genes, LenioBio partnership) support the long-term story but are already largely priced in at current levels.", "verdict": "no_anomaly", "confidence": 4, "tool_calls": 24, "walltime_min": 12, "debug_path": "dossiers/2026-05-29-TWST.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-22T09:41:08.092Z", "summary": "Investigation triggered by Form 4 cluster (2 real trades in 14 days) reveals both recent transactions are routine sell-to-cover events for RSU tax withholding — CEO Emily Leproust and CFO Robert Werner selling at market, not discretionary purchases. The stock is up 132% YTD on strong Q2 FY26 earnings (beat revenue estimates, raised full-year guidance to ~$460M), gross margins above 50%, and new product launches (Complex Genes, Invenra bispecific licensing). However, with forward P/E of -28.7, at/near 52-week high, no CEO/CFO open-market purchases present, and no identifiable mispricing vs. intrinsic value for a pre-profitability synthetic biology company, there is no anomaly to trade against. The pipeline halts.", "verdict": "no_anomaly", "confidence": 4, "tool_calls": 20, "walltime_min": 17, "debug_path": "dossiers/2026-05-22-TWST.scout.debug.json" }, { "type": "analyst_decision", "ts": "2026-05-15T15:44:30.809Z", "skip": true, "reason": "The dossier shows zero insider buying, persistent negative earnings/cash flow, and active dilution, while the stock has already surged 90% YTD leaving it fully valued with no margin of safety. Active anti-signals for dilution and pump behavior, combined with no clear asymmetric catalyst or technical support, firmly preclude a trade.", "score": 5, "breakdown": { "smart_money": 0, "options_flow": 0, "catalyst": 5, "mispricing": 0, "quality": 0, "technical": 0 }, "debug_path": "drafts/2026-05-15-TWST.analyst.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-15T15:43:59.323Z", "summary": "The Form 4 cluster trigger (7 filings / 5 real trades in last 14 days) turned out to be entirely routine: all five transactions on May 4, 2026 were sell-to-cover of RSU tax withholdings by mid-tier executives (Dennis Cho, Patrick Finn, Paula Green, Robert Werner). A sixth filing from director Jan Johannessen was an option-exercise-plus-same-day-sale at $56 — vesting exercise, not a discretionary open-market buy. Cathie Wood's ARK has been trimming TWST across multiple sessions in May 2026 while the stock ran +90% YTD to near 52-week highs of $66. The recent Q2 FY2026 earnings (May 4) did show a revenue beat and raised full-year guidance, with EBITDA breakeven targeted for Q4 FY2026 — but at -24x forward P/E on negative FCF and a stock that has already doubled year-to-date, the risk/reward does not support an asymmetric long. The elevated IV (74-95% ATM) makes this a plausible covered-call or strangle candidate rather than a directional setup.", "verdict": "range_bound_or_income", "confidence": 5, "tool_calls": 24, "walltime_min": 27, "debug_path": "dossiers/2026-05-15-TWST.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-08T20:34:43.239Z", "summary": "Twist Bioscience is a synthetic DNA manufacturer using proprietary silicon-chip technology, also operating in NGS tools and antibody discovery services. Revenue grew ~19% YoY to $409M TTM; still deeply unprofitable ($77.7M net loss FY2025). The investigation trigger was a Form 4 cluster of 7 filings in 14 days, but on thorough review ALL transactions are sell-to-cover (code S) for RSU tax withholding obligations — not open-market purchases. There is zero discretionary insider buying anywhere in the recent filing history. The May 4 Q2 FY2026 earnings report was a revenue beat with raised full-year guidance and an announced launch of Complex Genes; however, TWST trades near its 52-week high with no meaningful valuation discount, negative forward P/E, and the stock has already run ~110% in the past year. No edge-in-data anomaly was found.", "verdict": "no_anomaly", "confidence": 5, "tool_calls": 23, "walltime_min": 22, "debug_path": "dossiers/2026-05-08-TWST.scout.debug.json" } ], "lessons": [], "chart_signal": { "ticker": "TWST", "call": "BUY", "confidence": 5, "score": 8, "factors": { "above_200dma": "+2", "above_50dma": "+1", "momentum_strong_up": "+2 (64.1%)", "rsi_neutral": "0 (69.6)", "macd_above_signal": "+1", "recent_macd_bullish_cross": "+1 (20d ago)", "near_52w_high": "+1 (-2.9% from high)" }, "summary": "BUY (score +8) · 12-1 mom 64.1% · RSI 69.6 · above_both · -2.9% from high", "last_close": 85, "one_month_ago_close": 58.84, "twelve_month_ago_close": 35.85, "twelve_one_momentum_pct": 64.13, "rsi_14": 69.6, "ma_stack": "above_both", "from_period_high_pct": -2.92, "period_high": 87.56, "price_targets": { "bear": 36, "fair": 74.34, "bull": 100.69, "bear_return_pct": -57.6, "fair_return_pct": -12.5, "bull_return_pct": 18.5, "method": "street_targets ⨯ chart_floors", "street": { "target_low": 36, "target_mean": 74.1, "target_high": 95, "analyst_count": 10 } }, "generated_at": "2026-06-24T07:36:53.657Z" } }